Intra-Cellular Therapies (NASDAQ:ITCI) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Tuesday.

Other research analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a report on Tuesday, October 16th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $32.00 price target on shares of Intra-Cellular Therapies in a research report on Thursday, October 4th. ValuEngine lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research report on Thursday, November 15th. Finally, Leerink Swann started coverage on shares of Intra-Cellular Therapies in a research report on Tuesday, November 13th. They set an “outperform” rating and a $27.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $28.25.

Shares of ITCI opened at $13.82 on Tuesday. Intra-Cellular Therapies has a 12 month low of $13.78 and a 12 month high of $25.82.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.85) by $0.09. Equities analysts forecast that Intra-Cellular Therapies will post -3.03 earnings per share for the current fiscal year.

In other Intra-Cellular Therapies news, Director Joel S. Marcus sold 25,000 shares of the company’s stock in a transaction on Friday, November 9th. The shares were sold at an average price of $18.24, for a total transaction of $456,000.00. Following the sale, the director now directly owns 21,671 shares of the company’s stock, valued at $395,279.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Joel S. Marcus sold 32,000 shares of the company’s stock in a transaction on Monday, November 12th. The stock was sold at an average price of $18.17, for a total transaction of $581,440.00. Following the sale, the director now directly owns 21,671 shares in the company, valued at $393,762.07. The disclosure for this sale can be found here. Corporate insiders own 17.40% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Northern Trust Corp raised its position in shares of Intra-Cellular Therapies by 9.4% in the second quarter. Northern Trust Corp now owns 540,016 shares of the biopharmaceutical company’s stock valued at $9,542,000 after purchasing an additional 46,453 shares during the period. BlackRock Inc. raised its position in shares of Intra-Cellular Therapies by 1.1% in the second quarter. BlackRock Inc. now owns 3,794,986 shares of the biopharmaceutical company’s stock valued at $67,058,000 after purchasing an additional 41,856 shares during the period. Wasatch Advisors Inc. raised its position in shares of Intra-Cellular Therapies by 1.0% in the third quarter. Wasatch Advisors Inc. now owns 1,928,018 shares of the biopharmaceutical company’s stock valued at $41,838,000 after purchasing an additional 19,787 shares during the period. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Intra-Cellular Therapies in the second quarter valued at about $1,756,000. Finally, NumerixS Investment Technologies Inc bought a new position in shares of Intra-Cellular Therapies in the second quarter valued at about $167,000. 69.53% of the stock is currently owned by hedge funds and other institutional investors.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.

Featured Story: Book Value Of Equity Per Share – BVPS Explained

Analyst Recommendations for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.